Nureca

Why is Nureca Ltd falling/rising?

As of 28-Jul, Nureca Ltd's stock price is at 311.15, down 1.22% after a trend reversal. Despite a strong long-term performance, recent declines in price and investor participation suggest a temporary setback.

As of 28-Jul, Nureca Ltd's stock price is currently at 311.15, reflecting a decrease of 3.85 or 1.22%. The stock has experienced a trend reversal, falling after two consecutive days of gains. Today, it touched an intraday low of Rs 306.6, which is a decline of 2.67%. Additionally, the weighted average price indicates that more volume was traded closer to this low price, suggesting a lack of upward momentum.<BR><BR>Investor participation appears to be declining, with the delivery volume on 27 July falling by 15.22% compared to the 5-day average. This drop in participation may contribute to the stock's downward movement. Despite these short-term challenges, Nureca Ltd has shown strong performance over longer periods, with a 30.71% increase over the past month and a 29.13% increase over the past year. However, the current decline in price and investor participation indicates a temporary setback in the stock's performance.

Which are the latest news on Nureca?

Are Nureca Ltd latest results good or bad?

Nureca Ltd's latest results show strong revenue growth, achieving ₹40.34 crores with an 18.02% year-on-year increase, but profitability concerns arise due to reliance on non-operating income and a fragile operating margin of 8.48%. While there are positive trends, investors should be cautious about the sustainability of earnings.

Nureca Ltd's latest results present a mixed picture. On one hand, the company achieved its highest quarterly revenue in recent history at ₹40.34 crores, marking an impressive 18.02% year-on-year growth and a 13.92% sequential increase. This indicates strong top-line momentum and suggests that management's turnaround efforts are starting to bear fruit after a challenging previous fiscal year.<BR><BR>However, the profitability aspect raises concerns. While the net profit of ₹3.07 crores reflects a remarkable 279.01% increase year-on-year, this figure is somewhat misleading due to the low base from the previous year. Furthermore, a significant portion of the profit before tax—41.08%—came from other income, which raises questions about the sustainability of the company's core earnings. The operating margin improved to 8.48%, a notable recovery from a loss the previous year, yet it still highlights the fragility of the company's profitability.<BR><BR>Overall, while the quarterly performance shows positive trends in revenue and margin recovery, the heavy reliance on non-operating income and the underlying challenges in generating robust operational cash flows suggest that the results are not entirely positive. Investors should approach with caution, considering both the encouraging growth and the structural weaknesses that remain.

Should I buy, sell or hold Nureca Ltd?

When is the next results date for Nureca Ltd?

The next results date for Nureca Ltd is July 21, 2026.

The next results date for Nureca Ltd is scheduled for July 21, 2026.

What does Nureca do?

Nureca Ltd is a micro-cap company in the home healthcare and wellness sector, incorporated in India in 2016 and transitioned to a public company in 2020. As of March 2026, it reported net sales of 35 Cr and a net loss of 6 Cr, with a market cap of INR 223 Cr.

Overview:<BR>Nureca Ltd is engaged in the business of home healthcare and wellness products within the healthcare services industry and operates in the micro-cap market.<BR><BR>History:<BR>Nureca Ltd was incorporated as Nureca Private Limited in India on 02 November 2016. It transitioned from a Private Limited Company to a Public Limited Company on 08 July 2020. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 35 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -6 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 223 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 104.00 <BR>Industry P/E: 92 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.22 <BR>Return on Equity: 1.15% <BR>Price to Book: 1.26 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Nureca?

As of 10th June, Nureca Ltd has a market capitalization of 223.00 Cr, with recent net sales of 146.97 Cr and a net profit of 2.08 Cr. Shareholder's funds are 194.28 Cr, and total assets amount to 206.50 Cr as of March 2025.

As of 10th June, Nureca Ltd has a market capitalization of 223.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Nureca reported Net Sales of 146.97 Cr and a Net Profit of 2.08 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 194.28 Cr and Total Assets of 206.50 Cr.

Who are in the management team of Nureca?

The management team of Nureca includes Saurabh Goyal (Chairman & Managing Director), Aryan Goyal (Whole Time Director & CEO), and several Independent Directors: Vijay Kumar Sharma, Charu Singh, Ruchita Agarwal, and Vikram Chaudhary, along with Chetna Anand (Company Secretary & Compliance Officer). They oversee the company's strategic direction and regulatory compliance.

The management team of Nureca includes the following individuals:<BR><BR>1. **Saurabh Goyal** - Chairman & Managing Director<BR>2. **Vijay Kumar Sharma** - Independent Director<BR>3. **Charu Singh** - Independent Director<BR>4. **Ruchita Agarwal** - Independent Director<BR>5. **Vikram Chaudhary** - Independent Director<BR>6. **Chetna Anand** - Company Secretary & Compliance Officer<BR>7. **Aryan Goyal** - Whole Time Director & CEO<BR><BR>This team is responsible for guiding the company's strategic direction and ensuring compliance with regulatory requirements.

Who are the peers of the Nureca?

Nureca's peers include Hemant Surgical, Prevest Denpro, Take Solutions, Star Imaging, Jeevan Scientific, Bilcare, and QMS Medical. Hemant Surgical shows the highest 1-year return at 278.57%, while Nureca's return is -22.64%, slightly better than Prevest Denpro's -22.92%.

Peers: The peers of Nureca are Hemant Surgical, Prevest Denpro, Take Solutions, Star Imaging, Jeevan Scienti., Bilcare, and QMS Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Star Imaging, while Average management risk is found at Hemant Surgical and QMS Medical, and the rest. Good growth is seen at Hemant Surgical, while Below Average growth is noted for Prevest Denpro, Take Solutions, Nureca, Star Imaging, Jeevan Scienti., Bilcare, and the rest. Excellent capital structure is attributed to Prevest Denpro and Star Imaging, while Good capital structure is noted for Nureca, Average for Jeevan Scienti. and QMS Medical, and Below Average for Take Solutions, Bilcare, and the rest.<BR><BR>Return Snapshot: Hemant Surgical has the highest 1-year return at 278.57%, while Prevest Denpro has the lowest at -22.92%, with Nureca's own 1-year return at -22.64% being slightly better than Prevest Denpro's. Additionally, peers such as Prevest Denpro, Take Solutions, Bilcare, and QMS Medical have negative six-month returns.

How has been the historical performance of Nureca?

Nureca's historical performance has shown significant declines in net sales, operating profit, and profitability, with net sales dropping from 255.55 Cr in Mar'22 to 109.66 Cr in Mar'25, and operating profit turning negative by Mar'25. Despite slight increases in total assets and liabilities, the company has faced challenging financial conditions with negative cash flow from operating activities.

Answer:<BR>The historical performance of Nureca shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Nureca's net sales have varied considerably, peaking at 255.55 Cr in Mar'22 before declining to 109.66 Cr in Mar'25. The total operating income followed a similar trend, with a high of 255.55 Cr in Mar'22 and dropping to 109.66 Cr in Mar'25. The company's total expenditure, excluding depreciation, has also seen fluctuations, reaching a high of 200.04 Cr in Mar'22 and decreasing to 117.20 Cr in Mar'25. Operating profit, which was 63.21 Cr in Mar'22, turned negative in subsequent years, culminating in a loss of 7.54 Cr in Mar'25. Profit before tax showed a similar decline, moving from 60.98 Cr in Mar'22 to a modest profit of 1.34 Cr in Mar'25. The profit after tax also reflected this trend, with a significant drop from 44.96 Cr in Mar'22 to 0.85 Cr in Mar'25. The company's total assets increased slightly from 200.26 Cr in Mar'24 to 206.50 Cr in Mar'25, while total liabilities also rose from 200.26 Cr to 206.50 Cr in the same period. Cash flow from operating activities has been negative in recent years, with a notable outflow of 19.00 Cr in Mar'25. Overall, Nureca's financial performance indicates a challenging period with declining revenues and profitability, despite some stability in asset and liability levels.

Who are the top shareholders of the Nureca?

The top shareholders of Nureca include promoter Saurabh Goyal with 31.86%, individual investors with 32.39%, and four Foreign Institutional Investors holding 1.07%. The highest public shareholder is Nisarg Vakharia at 1.78%, with no mutual funds currently invested.

The top shareholders of Nureca include the promoters, who hold a significant portion of the company's shares. The promoter with the highest holding is Saurabh Goyal, owning 31.86% of the shares. Additionally, individual investors collectively hold 32.39% of the shares. In terms of institutional investors, there are four Foreign Institutional Investors (FIIs) that hold a total of 1.07%. The highest public shareholder is Nisarg Vakharia, with a holding of 1.78%. There are no mutual funds currently holding shares in Nureca.

Is Nureca overvalued or undervalued?

As of November 14, 2022, Nureca is considered overvalued with a high PE ratio of 287.01 and negative EV to EBIT and EBITDA ratios, leading to a valuation grade shift from very attractive to risky, despite a recent stock return of 5.53%.

As of 14 November 2022, the valuation grade for Nureca has moved from very attractive to risky, indicating a significant shift in its financial outlook. The company is currently assessed as overvalued, primarily due to its exceptionally high PE ratio of 287.01 and negative EV to EBIT and EV to EBITDA ratios of -24.77 and -32.45, respectively. Additionally, the return on capital employed (ROCE) stands at -6.50%, further highlighting the challenges the company faces in generating returns.<BR><BR>In comparison to its peers, Nureca's valuation metrics are starkly higher; for instance, Poly Medicure Ltd. has a PE ratio of 66.7 and an EV to EBITDA of 47.56, while Vimta Labs Ltd. shows a PE of 34.32 and an EV to EBITDA of 18.35. These comparisons underscore Nureca's overvaluation relative to its industry. Despite a recent stock return of 5.53% over the past week, which outperformed the Sensex's 1.39%, the overall financial indicators suggest that Nureca's current market price of 283.50 is not justified by its underlying performance.

What is the technical trend for Nureca?

As of June 3, 2025, Nureca's technical trend is mildly bullish, supported by weekly MACD, KST, and Dow Theory indicators, despite some caution from daily moving averages and mixed signals from Bollinger Bands.

As of 3 June 2025, the technical trend for Nureca has changed from sideways to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, supporting the positive outlook. The Dow Theory also aligns with this stance, indicating a mildly bullish trend on both weekly and monthly time frames. However, the daily moving averages are mildly bearish, which introduces some caution. The Bollinger Bands show a bullish signal on the weekly but a mildly bearish signal on the monthly, adding to the mixed signals. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, KST, and Dow Theory indicators.

Has Nureca declared dividend?

Nureca Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of February 24, 2022. However, the dividend yield is currently 0%, and the company has shown significant negative total returns over various periods.

Nureca Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 24 Feb 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -1.71%, the dividend return was 0%, resulting in a total return of -1.71%.<BR><BR>Over the past year, the price return was 8.92%, the dividend return was 0%, leading to a total return of 8.92%.<BR><BR>For the 2-year period, the price return was -26.2%, with a dividend return of 0%, resulting in a total return of -26.2%.<BR><BR>In the 3-year period, the price return was -73.96%, the dividend return was 0%, culminating in a total return of -73.96%.<BR><BR>Over the last 4 years, the price return was -81.2%, with a dividend return of 0.31%, resulting in a total return of -80.89%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Nureca Ltd has declared a dividend, the dividend yield is currently 0%, indicating that the company has not consistently provided dividends in recent periods. The total returns over various periods show significant volatility, particularly with negative returns in the longer terms.